clinical trial · NCT05127174
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
H. Lee Moffitt Cancer Center and Research Institute·phase1·terminated·n = 12
Myeloproliferative NeoplasmFedratinib Pill
brief summary
The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic cell transplant (HCT).
started
Mar 14, 2022
primary completion
Jan 3, 2025
completion
Jan 3, 2025
last updated
Dec 4, 2025
official title
A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol